These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12842334)

  • 1. The impurities of capreomycin make a difference in the safety and pharmacokinetic profiles.
    Lee SH; Shin J; Choi JM; Lee EY; Kim DH; Suh JW; Chang JH
    Int J Antimicrob Agents; 2003 Jul; 22(1):81-3. PubMed ID: 12842334
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model.
    Garcia-Contreras L; Fiegel J; Telko MJ; Elbert K; Hawi A; Thomas M; VerBerkmoes J; Germishuizen WA; Fourie PB; Hickey AJ; Edwards D
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2830-6. PubMed ID: 17517845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin.
    Fiegel J; Garcia-Contreras L; Thomas M; VerBerkmoes J; Elbert K; Hickey A; Edwards D
    Pharm Res; 2008 Apr; 25(4):805-11. PubMed ID: 17657592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capreomycin oleate microparticles for intramuscular administration: Preparation, in vitro release and preliminary in vivo evaluation.
    Cambronero-Rojas A; Torres-Vergara P; Godoy R; von Plessing C; Sepúlveda J; Gómez-Gaete C
    J Control Release; 2015 Jul; 209():229-37. PubMed ID: 25956458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A physiologically based pharmacokinetic model for capreomycin.
    Reisfeld B; Metzler CP; Lyons MA; Mayeno AN; Brooks EJ; Degroote MA
    Antimicrob Agents Chemother; 2012 Feb; 56(2):926-34. PubMed ID: 22143528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety.
    Singh H; Jindal S; Singh M; Sharma G; Kaur IP
    Int J Pharm; 2015 May; 485(1-2):138-51. PubMed ID: 25769294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UV spectroscopy and reverse-phase HPLC as novel methods to determine Capreomycin of liposomal fomulations.
    Rossi C; Fardella G; Chiappini I; Perioli L; Vescovi C; Ricci M; Giovagnoli S; Scuota S
    J Pharm Biomed Anal; 2004 Oct; 36(2):249-55. PubMed ID: 15496317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capreomycin inhalable powders prepared with an innovative spray-drying technique.
    Schoubben A; Giovagnoli S; Tiralti MC; Blasi P; Ricci M
    Int J Pharm; 2014 Jul; 469(1):132-9. PubMed ID: 24747443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple and scalable method for peptide inhalable powder production.
    Schoubben A; Blasi P; Giovagnoli S; Ricci M; Rossi C
    Eur J Pharm Sci; 2010 Jan; 39(1-3):53-8. PubMed ID: 19879945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting.
    Nimje N; Agarwal A; Saraogi GK; Lariya N; Rai G; Agrawal H; Agrawal GP
    J Drug Target; 2009 Dec; 17(10):777-87. PubMed ID: 19938949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pyridoxine on rifampicin toxicity.
    Yun YP; Kim KH; Kim HS; Chung JH
    Arch Pharm Res; 1991 Mar; 14(1):73-7. PubMed ID: 10319125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation and identification of four major impurities in capreomycin sulfate.
    Liu G; Luan B; Liang G; Xing L; Huang L; Wang C; Xu Y
    J Chromatogr A; 2018 Oct; 1571():155-164. PubMed ID: 30115387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
    Rawal T; Kremer L; Halloum I; Butani S
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery.
    Giovagnoli S; Blasi P; Schoubben A; Rossi C; Ricci M
    Int J Pharm; 2007 Mar; 333(1-2):103-11. PubMed ID: 17079101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The copper (II) ion as a carrier for the antibiotic capreomycin against Mycobacterium tuberculosis.
    Manning T; Mikula R; Lee H; Calvin A; Darrah J; Wylie G; Phillips D; Bythell BJ
    Bioorg Med Chem Lett; 2014 Feb; 24(3):976-82. PubMed ID: 24424129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRELIMINARY LABORATORY STUDIES WITH CAPREOMYCIN.
    BLACK HR; GRIFFITH RS; BRICKLER JF
    Antimicrob Agents Chemother (Bethesda); 1963; 161():522-9. PubMed ID: 14274954
    [No Abstract]   [Full Text] [Related]  

  • 17. Capreomycin kinetics in renal impairment and clearance by hemodialysis.
    Lehmann CR; Garrett LE; Winn RE; Springberg PD; Vicks S; Porter DK; Pierson WP; Wolny JD; Brier GL; Black HR
    Am Rev Respir Dis; 1988 Nov; 138(5):1312-3. PubMed ID: 2462388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAPREOMYCIN SUSCEPTIBILITY OF STRAINS RESISTANT TO STREPTOMYCIN AND/OR VIOMYCIN.
    VERBIST L; GYSELEN A
    Am Rev Respir Dis; 1964 Oct; 90():640-1. PubMed ID: 14221679
    [No Abstract]   [Full Text] [Related]  

  • 19. Rifapentine for the treatment of tuberculosis: is it all it can be?
    Gordin FM
    Am J Respir Crit Care Med; 2004 Jun; 169(11):1176-7. PubMed ID: 15161608
    [No Abstract]   [Full Text] [Related]  

  • 20. [ON THE PROBLEM OF ANTIMYCOBACTERIAL EFFECT AND CROSS RESISTANCE OF CAPREOMYCIN].
    TRNKA L; KUSKA J; HAVEL A
    Prax Pneumol; 1964 Dec; 18():798-802. PubMed ID: 14335595
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.